PTC Therapeutics, Inc.
PTCT
$46.39
$0.380.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.18B | 213.17M | 196.79M | 186.70M | 210.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18B | 213.17M | 196.79M | 186.70M | 210.12M |
| Cost of Revenue | 121.84M | 141.05M | 172.26M | 147.70M | 130.87M |
| Gross Profit | 1.05B | 72.12M | 24.53M | 39.01M | 79.25M |
| SG&A Expenses | 80.96M | 84.68M | 73.46M | 69.50M | 73.27M |
| Depreciation & Amortization | 3.80M | 3.31M | 3.04M | 2.87M | 51.53M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.59M | 229.04M | 248.75M | 220.06M | 255.67M |
| Operating Income | 969.50M | -15.87M | -51.97M | -33.36M | -45.55M |
| Income Before Tax | 929.83M | -94.70M | -97.99M | -85.73M | -84.70M |
| Income Tax Expenses | 63.27M | -28.81M | 8.66M | 13.45M | 6.88M |
| Earnings from Continuing Operations | 866.56M | -65.89M | -106.65M | -99.18M | -91.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 866.56M | -65.89M | -106.65M | -99.18M | -91.58M |
| EBIT | 969.50M | -15.87M | -51.97M | -33.36M | -45.55M |
| EBITDA | 976.72M | -9.11M | -45.48M | -26.34M | 9.84M |
| EPS Basic | 11.09 | -0.85 | -1.39 | -1.29 | -1.20 |
| Normalized Basic EPS | 7.45 | 0.36 | -0.82 | -0.61 | -0.70 |
| EPS Diluted | 10.04 | -0.85 | -1.39 | -1.29 | -1.20 |
| Normalized Diluted EPS | 6.74 | 0.36 | -0.82 | -0.61 | -0.70 |
| Average Basic Shares Outstanding | 78.12M | 77.20M | 76.93M | 76.73M | 76.50M |
| Average Diluted Shares Outstanding | 86.39M | 77.20M | 76.93M | 76.73M | 76.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |